DYADIC INTERNATIONAL INC Number of Reportable Segments
DYADIC INTERNATIONAL INC (DYAI) reported Number of Reportable Segments of 1 Segment for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Notes › Segment Reporting
us-gaap:NumberOfReportableSegments · last filed 2026-08-12
- DYADIC INTERNATIONAL INC number of reportable segments for the quarter ending 2025-03-31 was 100.00%.
- DYADIC INTERNATIONAL INC number of reportable segments for fiscal 2024 was 100.00%.
pure
| Period end | Number of Reportable Segments 3 month | Number of Reportable Segments 12 month |
|---|---|---|
| 2025-03-31 | 100.00% 10-Q · filed 2025-05-14 | |
| 2024-12-31 | 100.00% 10-K · filed 2025-03-26 |
Segment
| Period end | Number of Reportable Segments 3 month | Number of Reportable Segments 6 month | Number of Reportable Segments 9 month | Number of Reportable Segments 12 month |
|---|---|---|---|---|
| 2026-06-30 | 1.00 Segment 10-Q · filed 2026-08-12 | |||
| 2026-03-31 | 1.00 Segment 10-Q · filed 2026-05-13 | |||
| 2025-12-31 | 1.00 Segment 10-K · filed 2026-03-25 | |||
| 2025-09-30 | 1.00 Segment 10-Q · filed 2025-11-12 | |||
| 2025-06-30 | 1.00 Segment 10-Q · filed 2025-08-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| Pluri Inc. (PLUR) | $0.014B | ||
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| Estrella Immunopharma, Inc. (ESLA) | United States | $0.020B | |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |